📊 Get daily AI-graded market briefings
Morning + evening · AI impact + sector exposure · Free
LAST 30 DAYS
0 articles
AVG GRADE
HIGH
score: 0.50
SENTIMENT
BULLISH
TOTAL VIEWS
35
CANF Latest News & AI Sentiment Analysis
0 articles · Grade: HIGH · Real-time AI-graded coverage
RECENT COVERAGE · 6 ARTICLES
Can-Fite Achieves Key Pivotal Phase 3 Psoriasis Milestone with Completion of Patient Enrolment for the Interim Analysis: Data Expected Q4 2026/Q1 2027
Can-Fite Pharmaceuticals (CANF) has completed patient enrollment for an interim analysis in its Phase 3 psoriasis trial, representing a...
Top Biotech Gainers: CANF Climbs, RGNT Gears Up For Europe Launch, RNAZ, ELTX On Watch
CANF, RGNT, RNAZ, and ELTX are trading higher on positive clinical and commercial developments within the biotech sector. These gains...
Can-Fite Phase 2a Pancreatic Cancer Study with Namodenoson Achieves Primary Safety Endpoint and Demonstrates Durable Survival Outcomes in Advanced Disease
Can-Fite Pharmaceuticals (CANF) reported positive interim Phase 2a data for namodenoson in advanced pancreatic cancer, marking a...
Can-Fite Secures Japanese Patent Allowance for Namodenoson's Anti-Obesity Technology
Can-Fite Pharmaceuticals has achieved Japanese patent allowance for Namodenoson, its anti-obesity compound candidate. This regulatory...
Can-Fite Publishes Peer-Reviewed Scientific Article Demonstrating the Broad Therapeutic Potential of Piclidenoson and Namodenoson
Can-Fite BioPharma (CANF) has published peer-reviewed research validating its lead compounds, Piclidenoson and Namodenoson, across...
Can-Fite to Present Late-Stage Clinical Pipeline and Licensing Opportunities at BIO International Convention 2026
Can-Fite Pharmaceuticals announced participation at the BIO International Convention 2026, where management will present its late-stage...
E
ESEN Analytics
AI-powered equity research platform covering 5,000+ US equities. Our proprietary AI grading system (A+ to D scale) analyzes fundamentals, technicals, and news sentiment daily. Coverage data updated every 24 hours.
Learn about our methodology →
ⓘ AI-graded news coverage · Not investment advice